DEC 26, 2017 11:44 AM PST

Nanoparticles Improve Chemotherapy Via Anti-tumor Immunity

Doxorubicin, tradename Adriamycin, is a well known chemotherapeutic agent used to treat a variety of cancer types including lymphoma, leukemia, myeloma, breast, stomach, lung, thyroid, and bladder cancer, and Kaposi’s sarcoma. It is typically administered by intravenous or iv injection, and is associated with unpleasant toxicities and side effects. It was first approved for use in the United States in 1974, so it is safe to say it has been around for quite some time now. Doxorubicin works by intercalating into DNA, thereby preventing DNA replication progression and cell division, ultimately leading to cell death. This is great for killing of cancer cells, but it is not selective and hits healthy, non-cancerous cells as well.

The lab of Dr. Ashutosh Chilkoti at Duke University in North Carolina has recently shown that nanoparticle formulation can improve the efficacy of doxorubicin through increase in anti-tumor immune response, and the results of this study are set to be published in January (2018) in the Journal of Controlled Release. Nanoparticles themselves have been a topic of interest for therapeutics of late, and harnessing anti-tumor immune response has proven an effective hot area of study for cancer treatment over the past several years. In the above mentioned study, they utilize both approaches in an effort to improve cancer therapy. 

Doxorubicin can contribute to establishing anti-tumor immunity through enhancing immune-mediated cell death. Dr. Chilkoti’s group show that use of a nanoparticle formulation of doxorubicin which they call CP-Dox (short for Chimeric Polypeptide Doxorubicin), can enhance such antitumor immunity. They compare traditional “free” doxorubicin to a single, iv injection of CP-Dox at the maximum tolerated dose into tumors in mice, and find there is a resulting increase in the number of infiltrating leukocytes and subsequent decrease in tumor growth and metastasis. They go on to show that these results are dependent upon CD8 positive T-cells, otherwise known as the “killer” T-cells, as well as interferon-gamma. The treatment was also found to impact myeloid cell polarization within the tumor itself toward an anti-tumor phenotype. Overall this shows the efficacy of a nanoparticle-based chemotherapeutic (that is doxorubicin) and its ability to elicit anti-tumor immunity, in a manner distinct from the traditional “free” chemotherapy. The authors conclude that this study “strongly argues for the use of anti-tumor immunotherapies combined with nanoparticle-packaged chemotherapy” to combat cancer more effectively.

Sources: Journal of Controlled Release, Wikipedia, Pixabay

About the Author
You May Also Like
NOV 23, 2018
Cannabis Sciences
NOV 23, 2018
Rimonabant: A Cautionary Tale for Targeting the Endocannabinoid System
The evidence that the endocannabinoid system (ECS) is intimately involved in food intake has been steadily increasing. Thus, in attempts to treat obesity,...
DEC 11, 2018
Cancer
DEC 11, 2018
FDA approves two new drugs for cancers with specific genetic mutations
Last month the FDA approved two new drugs for cancer, both drugs target cancers with specific genetic mutations which made geneticists and oncologists optimistic on the future of cancer thera...
DEC 23, 2018
Drug Discovery
DEC 23, 2018
Super-Drug for Pediatric Leukemia?
In a final study published in Genes & Development, researchers at Northwestern University School of Medicine concluded their discoveries on two success...
JAN 07, 2019
Cell & Molecular Biology
JAN 07, 2019
Researchers Develop an Experimental Therapy for Triple-negative Breast Cancer
Between 12 and 17% of all breast cancer cases are triple-negative, a highly aggressive type with few therapeutic options....
JAN 07, 2019
Drug Discovery
JAN 07, 2019
First-in-Human Trial of Senolytic Drugs
According to a study published in the journal EBioMedicine, the very first results on the treatment of a deadly age-related disease in human patients using...
JAN 23, 2019
Drug Discovery
JAN 23, 2019
Frequent Aspirin Use Can Lead to Increased Bleeding
According to a systemic study published in the Journal of the American Medical Association (JAMA), taking aspirin regularly may prevent heart attacks and s...
Loading Comments...